SG11201607642RA - Lyophilized factor ix formulations - Google Patents

Lyophilized factor ix formulations

Info

Publication number
SG11201607642RA
SG11201607642RA SG11201607642RA SG11201607642RA SG11201607642RA SG 11201607642R A SG11201607642R A SG 11201607642RA SG 11201607642R A SG11201607642R A SG 11201607642RA SG 11201607642R A SG11201607642R A SG 11201607642RA SG 11201607642R A SG11201607642R A SG 11201607642RA
Authority
SG
Singapore
Prior art keywords
formulations
lyophilized factor
lyophilized
factor
Prior art date
Application number
SG11201607642RA
Other languages
English (en)
Inventor
Brian M Thome
Cherie Parkhurst-Lang
Brandon W Leveille
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607642R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SG11201607642RA publication Critical patent/SG11201607642RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201607642RA 2014-03-24 2015-03-24 Lyophilized factor ix formulations SG11201607642RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24
PCT/US2015/022141 WO2015148444A1 (fr) 2014-03-24 2015-03-24 Formulations de facteur ix lyophilisées

Publications (1)

Publication Number Publication Date
SG11201607642RA true SG11201607642RA (en) 2016-10-28

Family

ID=54196282

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201808249VA SG10201808249VA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations
SG10201913735SA SG10201913735SA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations
SG11201607642RA SG11201607642RA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201808249VA SG10201808249VA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations
SG10201913735SA SG10201913735SA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Country Status (17)

Country Link
US (2) US10772942B2 (fr)
EP (1) EP3123090A4 (fr)
JP (4) JP7058940B2 (fr)
KR (1) KR102385372B1 (fr)
AR (1) AR099838A1 (fr)
AU (3) AU2015236340B2 (fr)
BR (1) BR112016021777A2 (fr)
CA (1) CA2943034C (fr)
CL (1) CL2016002386A1 (fr)
EA (2) EA202092926A3 (fr)
IL (3) IL247869B (fr)
MA (1) MA39779A (fr)
MX (2) MX2016012447A (fr)
PH (1) PH12016501877A1 (fr)
SG (3) SG10201808249VA (fr)
TW (1) TWI700101B (fr)
WO (1) WO2015148444A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
MX2016012447A (es) 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
BR112020000592A2 (pt) * 2017-07-11 2020-07-14 Universal Stabilization Technologies, Inc. método para conservar materiais biológicos
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN115867307A (zh) * 2020-05-11 2023-03-28 奥克梅斯制药爱尔兰有限公司 Il-2融合多肽组合物以及其制备和使用方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1652534A3 (fr) * 1992-10-02 2007-05-02 Genetics Institute, LLC Composition comprenant une formulation d'un facteur de coagulation VIII, procédé pour sa préparation et utilisation d'un agent tensioactif comme stabilisateur
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (fr) 1996-10-16 2000-09-09 Alza Corp
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
EP1219298A4 (fr) 1999-09-17 2003-06-11 Takeda Chemical Industries Ltd Procede de production d'une poudre proteique
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
WO2002040544A2 (fr) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Facteur ix humain mutant a resistance accrue a l'inhibition par l'heparine
RU2004110239A (ru) 2001-09-04 2005-10-20 Мерк Патент ГмбХ (DE) Модифицированный фактор ix
EP1463751B1 (fr) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
WO2005089712A1 (fr) 2004-03-04 2005-09-29 Wyeth Procede de lyophilisation permettant d'ameliorer la cristallisation de l'excipient
WO2006029467A1 (fr) * 2004-09-16 2006-03-23 Btf Pty Ltd Traitement de lyophylisation rapide
CN101124331B (zh) 2004-11-12 2013-04-24 拜尔健康护理有限责任公司 Fvⅲ的位点定向修饰
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007014073A2 (fr) 2005-07-22 2007-02-01 Amgen Inc. Lyophilisats proteiques concentres, procedes associes et leurs utilisations
WO2007044616A2 (fr) * 2005-10-06 2007-04-19 Xencor, Inc. Anticorps anti-cd30 optimises
EP1942868B2 (fr) * 2005-11-01 2023-10-04 Wyeth LLC Solution de chlorure de sodium pour la reconstitution ou la dilution de medicaments
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
HUE042402T2 (hu) 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
EP2423307A1 (fr) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Polypeptides du facteur IV à coagulation modifiée et leur utilisation pour le traitement
US8015841B2 (en) * 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
DK2173890T3 (da) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
EP2209487A4 (fr) 2007-10-15 2012-06-20 Univ North Carolina Variantes du facteur ix humain qui présentent une demi-vie prolongée
KR20100110799A (ko) 2007-12-27 2010-10-13 백스터 인터내셔널 인코포레이티드 화학적으로 변형된 제 ９ 인자
KR20110015551A (ko) 2008-04-16 2011-02-16 바이엘 헬스케어 엘엘씨 제ｉｘ인자의 부위-지정 변형
AU2009244633A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified Factor IX polypeptides and uses thereof
EP2268807A2 (fr) 2008-04-21 2011-01-05 Novo Nordisk A/S Facteur ix de coagulation humain hyperglycosylé
CA2729972C (fr) 2008-08-05 2018-11-20 Wyeth Llc Lyophilisation au-dessus de la temperature d'effondrement
BRPI0918988A2 (pt) 2008-09-24 2015-12-01 Stabilitech Ltd métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2011017070A1 (fr) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Procédés de production de formulations pharmaceutiques lyophilisées à concentration élevée
KR20140017480A (ko) * 2010-07-09 2014-02-11 바이오겐 이데크 헤모필리아 인코포레이티드 인자 iｘ 폴리펩티드 및 이들의 사용 방법
ES2561878T3 (es) 2010-09-30 2016-03-01 Toyama Chemical Co., Ltd. Sal de meglumina de 6-fluoro-3-hidroxi-2-pirazinacarboxamida
EP2672986B1 (fr) 2011-02-09 2020-03-18 GlaxoSmithKline LLC Formulations lyophilisées
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
SG10201707600XA (en) * 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
MX2016012447A (es) * 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.

Also Published As

Publication number Publication date
MX2016012447A (es) 2017-01-06
IL272257B (en) 2021-03-25
IL247869A0 (en) 2016-11-30
CL2016002386A1 (es) 2017-06-23
JP2017510585A (ja) 2017-04-13
IL272257A (en) 2020-02-27
MX2021012939A (es) 2021-11-25
TWI700101B (zh) 2020-08-01
IL281197B (en) 2022-06-01
CA2943034C (fr) 2022-06-14
NZ724351A (en) 2023-10-27
SG10201913735SA (en) 2020-03-30
MA39779A (fr) 2017-02-01
JP2020063313A (ja) 2020-04-23
TW201605492A (zh) 2016-02-16
EA038573B1 (ru) 2021-09-16
AU2020202863B2 (en) 2022-09-01
IL281197A (en) 2021-04-29
EP3123090A4 (fr) 2017-12-13
JP7058940B2 (ja) 2022-04-25
US10772942B2 (en) 2020-09-15
AU2015236340A1 (en) 2016-09-29
AR099838A1 (es) 2016-08-24
AU2020202863A1 (en) 2020-05-21
SG10201808249VA (en) 2018-10-30
PH12016501877A1 (en) 2016-12-19
CA2943034A1 (fr) 2015-10-01
WO2015148444A1 (fr) 2015-10-01
US20170173122A1 (en) 2017-06-22
AU2015236340B2 (en) 2020-02-06
EA202092926A3 (ru) 2021-10-29
EA201691807A1 (ru) 2017-03-31
EP3123090A1 (fr) 2017-02-01
KR102385372B1 (ko) 2022-04-11
KR20160137577A (ko) 2016-11-30
JP2024053015A (ja) 2024-04-12
EA202092926A2 (ru) 2021-07-30
BR112016021777A2 (pt) 2017-10-03
IL247869B (en) 2020-02-27
US20210069307A1 (en) 2021-03-11
AU2022215218A1 (en) 2022-09-01
JP2022044689A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
TWD174427S (zh) 刮勺
GB201407934D0 (en) Formulation
GB2538413B (en) Blower
IL281197B (en) Formulations of factor ix that have been lyophilized
IL276960B (en) Lyophilized formulations for factor xa antidote
GB2530868B (en) Blower
GB201419261D0 (en) Formulations
GB201419091D0 (en) Formulations
IL248835A0 (en) A preparation of ciritinib
GB201407384D0 (en) Formulation
IL251362A0 (en) formulation
GB201402448D0 (en) Novel formulation
GB201511301D0 (en) Formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
GB201412754D0 (en) Formulation
GB201410184D0 (en) Odontalgic preparation
GB201404773D0 (en) Formulation
TWM490682U (en) Storagable extension-cord socket structure
GB201405857D0 (en) Immunogenic formulations
GB201406863D0 (en) Compositions comprising variegin